Introduction
Over the last two decades, the number of individuals infected with HIV has markedly increased. Since the introduction of the highly active antiretroviral therapy (HAART) at the end of 1995, the number of deaths caused by HIV infection or by an acquired immunodeficiency syndrome (AIDS)-defining disease has dramatically decreased 1 . HAART has increased survival and therefore extended the mean age of our population, but this prolongation has been accompanied by the emergence of acute and chronic kidney disease (CKD) and subsequent end-stage renal disease (ESRD) as major causes of morbidity and mortality in these patients 2 . Now, nephrologists are faced with several challenges regarding kidney disease in HIV-infected populations including identifying early signs of kidney disease, and working in collaboration with HIV experts to provide the best treatment to patients with renal disease. Renal disease is becoming an increasingly prevalent entity in HIV-infected patients and occurs at all stages of HIV infection. Renal pathology in HIV patients can be caused by a variety of mechanisms creating a broad spectrum of clinical disease. HIV-related renal impairment can present as acute or chronic kidney disease; it can be caused directly or indirectly by HIV and/or by drug-related effects that are directly nephrotoxic or lead to changes in renal function by inducing metabolic vaculopathy and renal damage 3 . The aim of this review was to give an overview of nephropathies in HIV-infected patients.
Acute renal failure in HIV-infected patients RIFLE and AKIN (the acronyms for diagnosis and classification of acute renal dysfunction) criteria are frequently used, and aim to standardize the definition of acute kidney injury (AKI) by stratifying patients based on changes in serum creatinine levels from baseline and/or an abrupt decrease in urine output. Tubular dysfunction is defined as an abnormal presence of markers in urine (e.g., hyperaminoaciduria, euglycemic glucosuria, beta2-microglobulinuria, and hyperphosphaturia) 4 . AKI is a common finding in HIV-infected patients and has been associated with advanced stages of HIV infection (e.g., CD4 cell count of < 200 cells/ mm 3 and HIV RNA level of > 10,000 copies/mL), with prior renal impairment, HCV co-infection, liver disease, and a history of HAART. HIV-infected patients are also at increased risk for AKI development, related to volume in HIV-seropositive patients in New York City. It was directly linked to infection of epithelial cells by HIV 14 , and was recently found to be related to polymorphisms in the APOL1 gene; indeed, almost all patients developing HIVAN are of African origin 14, 15 . Renal biopsy is the only means of establishing the diagnosis of HIVAN. Without adequate treatment, the prognosis of HIVAN is poor; risk factors for the development of HIVAN include a CD4 cell count < 200 cells/mm³ and a high viral burden 16 . Pharmacologic agents used for the treatment of HIVAN include HAART 17 , steroids, and angiotensin-converting enzyme inhibitors (ACEi). Recently, cyclosporin has been used as another option in children, but clinical experience with it is limited 4 . The introduction of HAART was shown to be associated with a reduction in HIVAN incidence 17 . Thrombotic microangiopathy, haemolytic uremic syndrome, and thrombotic thrombocytopenic purpura present a spectrum of diseases characterized by haemolytic anaemia, thrombocytopenia, renal insufficiency, and clinical features, such as fever and neurological manifestations. Several reports have linked thrombotic microangiopathy to HIV infection, suggesting that HIV proteins may mediate endothelial dysfunction, leading to platelet deposition in the microvasculature. Therapeutic options consist of plasma infusion and plasmapheresis, which have had variable success. Other attempted therapies include glucocorticoids, immunoglobulin infusions, antiplatelet drugs, vincristin, and splenectomy, although general treatment recommendations are lacking 8, 12 . Other pathophysiological pathways comprise indirect viral effects, such as various forms of deposition of HIV immune-complex kidney disease (HIVICK). The prevalence of HIVICK is highly variable in the different studies. A study of 60 biopsies found that some form of HIVICK was present in 37% of biopsy specimens. HIVICK may present as post-infectious tion. Pulmonary and disseminated TB and other viral infections such as cytomegalovirus (CMV), hepatitis B (HBV), and HCV should be included in the differential diagnosis of acute orchronic renal failure. It has been shown that patients who survive AKI have a greater rate of long-term mortality. Choi and colleagues evaluated the long-term consequences of AKI in 17.325 HIV-infected patients during their first hospitalization. Over a mean follow-up period of 5.7 years, they found that AKI was associated with increased mortality and longterm risk of heart failure, cardiovascular disease, and end-stage renal disease 3 .
Chronic Renal Disease in HIVInfected Patients
The prevalence of CKD in the various stages of HIV infection is difficult to assess. Proteinuria and elevated creatinine level have been found in 7.2%-32% of HIV-seropositive patients in a study of 2038 female HIVinfected patients 7 . Autopsy studies yield a prevalence of up to 43% of pathological changes on histological examination 8 . The cause of CKD in HIV-infected patients can be difficult to assess on clinical grounds alone and can most often only be determined by renal biopsy. CKD is defined by KDIGO and is divided into groups based on confirmed eGFR levels (≥ 3 months) 9 . CKD can be caused by multiple pathophysiological mechanisms; HIV itself seems to directly mediate the development of HIV-associated nephropathy (HIVAN) and thrombotic thrombocytopenic purpura. One of the main causes of CKD is HIVAN, a clinicopathologic entity characterized by severe proteinuria, renal failure, rapid progression to ESRD, and frequently enlarged kidneys visible on renal ultrasound [10] [11] [12] [13] .
It was initially described in 1984 by
Rao, who reported a pattern of focal segmental glomerulosclerosis, often of the collapsing variant, and microcystic tubulointerstitial disease depletion, sepsis, radiocontrast, and the administration of nephrotoxic medications used in the treatment of opportunistic infections, such as antibiotics (aminoglycosides), anti-fungals (amphotericin B), antivirals (acyclovir, ganciclovir), antituberculosis drugs, pentamidine, and anti-inflammatory drugs. A study that evaluated the incidence and aetiology in a prospective analysis of 754 HIV-infected patients reported an incidence of 5.9 cases of AKI per 100 patient-years 5 . In the HAART era, the reported incidence of AKI in hospitalized HIV-infected patients ranged from 6% to 20%, and AKI was associated with increased inhospital mortality 6 . Acute interstitial nephritis (AIN) can occur as a result of HIV infection of the kidney itself, as in 28% of autopsy findings in HIV-infected patients 4 . Interruption of the potential liable agent is the pivot of therapy. These complications can be prevented or minimized with wide fluid intake 4 . In severe cases, immunosuppressive therapy has been employed. Electrolyte disturbances of hypo-hypernatraemia, hypophosphataemia, hypocalcaemia, and hypomagnesaemia are common. Hyponatraemia is often observed in HIV-infected patients with gastroenteritis. The syndrome of inappropriate anti-diuretic hormone secretion (SIADH) is usually due to intracranial and respiratory infections such as pulmonary tuberculosis (TB), pneumocystis pneumonia, and toxoplasmosis. Hypokalaemia due to gastrointestinal losses, renal tubular loss, and severe malnutrition is also often found. Toxicity from HAART such as tenofovir can cause Fancony syndrome and nephrogenic diabetes insipidus. Therefore, the dosing of nephrotoxic drugs should be adjusted to the eGFR in patients with acute or chronic kidney damage. There is a higher prevalence of urinary tract infections (UTIs) and seem to be more due to malnutrition than from immunosuppression due to HIV infec-of osteoporosis, which is four times higher than the general population. According to the information Italian cohort naive antiretro virals (ICONA), more than 54% of patients with HIV infection lack vitamin D 21 . The virus has a direct responsibility in the pathogenesis of osteoporosis by acting on osteoblasts and osteoclasts. HAART also promotes the toxic action of the HIV virus on bone, as demonstrated by Brown in 2006 and by the SMART study 21 . These drugs act on the mitochondrial DNA, resulting in an increased production of lactic acid. Chronic metabolic acidosis causes an increase in osteoclastic activity and a reduction in osteoblastic activity 21 . Acid-base disturbances are common in HIV-infected patients and are mainly due to drugs and sepsis. Lactic acidosis may possibly be due to drug-induced mitochondrial dysfunction reported with zidovudine, stavudine, lamivudine, and diadanosine, and could be present in a mild form in 5%-25% of patients 4, 12, 22 . Non-anion gap metabolic acidosis can result from intestinal loss of bicarbonate due to diarrhoea or renal losses due to drug toxicity, most commonly amphotericin B and tenofovir 12, 22 .
Materials and methods
We conducted a review of the current knowledge on acute and chronic HIVassociated renal disease, metabolic alterations and related nephropathies, and toxic drug effects of HAART.
Types of studies
All RCTs and quasi-RCTs evaluate the current knowledge on acute and chronic HIV-associated renal disease, metabolic alterations and related nephropathies, and toxic drug effects of HAART.
Electronic searches
• Cochrane Renal Group's specialized register • AEGIS database (AIDS Education Global Information System) and diabetes, with an increase in secondary renal damage, such as hypertensive nephrosclerosis and diabetic glomerulopathy as well as vascular complications 21 . Antiretroviral therapy has been associated with impaired glucose tolerance. A study of 17,852 HIV-seropositive patients evaluated a prevalence of diabetes of 2.5% that was significantly associated with antiretroviral treatment 5 , and a study that ob Another study, including 60 kidney biopsies performed during AKI served a cohort of 5578 patients during 1984-2003 revealed an incidence of hypertension in 7.3% of HIV-seropositive patients 5 .
Renal damage caused by HAART can result in a variety of toxic drug effects presenting as acute renal failure, tubular necrosis, kidney stones, or CKD. HAART-associated nephrotoxicity has been described in many case reports and systematic observational studies; most studies, however, conclude that the occurrence is relatively low, but warrant clinical attention due to the potentially serious complications. One study found that HAART-related nephrotoxicity accounted for 14% of all AKI cases among HIV-positive individuals 3 . Another study, including 60 kidney biopsies performed during AKI, found 5% were HAART-related 5 . For tenofovir, Gilead has reported a 0.5% incidence of serious adverse renal events 12 . There are several direct and indirect ways in which HAART can induce damage to renal structures, as shown in Table 1 . There is an ongoing and unresolved discussion whether HAART-induced nephrotoxicity is reversible. Several studies demonstrate that only some patients reached preexposure levels, whereas several safety studies indicate a faster and more complete resolution after discontinuation 15, 16 . The contribution of HIV as well as HAART to bone disease, which may include loss of bone mineral content and aseptic necrosis of the femoral head, remains unclear. HIV patients are at an increased risk glomerulonephritis and includes membranous nephropathy, IgA nephropathy, lupus-like glomerulonephritis, fibrillary glomerulonephritis, immunotactoid glomerulopathy, and membranoproliferative glomerulonephritis 4, 18 . Cryoglobulinemic membranoproliferative glomerulonephritis (MPGN) is the more characteristic renal disease associated with HCV infection; indeed, HCV co-infection in HIV patients is a very common problem, affecting approximately 30% of HIV-infected patients. Patients with HIVIC seem to benefit from treatment with ACEi, glucocorticoids, and antiretrovirals 12, 19 . CKD is a serious complication of long-term intravenous drug use (IVDU). Renal diseaserelated IVDU has been reported since the 1970s, mostly in the context of heroin-associated nephropathy, characterized by nephritic syndrome and rapid progression 20 . Two recent studies from Europe observed changing patterns of renal disease in patients with IVDU, with concomitant chronic HIV, HBV, and HCV infections, reporting an increased prevalence of renal AA-amyloidosis. Renal AA-amyloidosis is a complication of chronic and/ or recurrent inflammatory disease. Severe proteinuria, nephrotic syndrome, as well as renal insufficiency are the typical clinical manifestations of renal AA-amyloidosis. Successful treatment of the underlying inflammation, by immunosuppressants for autoimmune diseases or by antimicrobials for chronic infections, can lead to stabilization of or even improvements in renal function 20 .
Renal adverse effects of HAART
The use of HAART has changed the natural history and spectrum of kidney disease in HIV-positive patients. HAART is effective in controlling the viral replication, restoring immune function, and decreasing the occurrence of HIV-related complications; however, it may be associated with nephrotoxicity or with increased rates of dyslipidaemia, hypertension, tion of HAART, the morbidity and mortality of HIV-infected patients was too high to justify using scarce resources to transplant HIV-infected patients. The ability to suppress HIV replication with HAART, as well as improved prophylaxis and treatment of opportunistic infections, encouraged the transplant community to select patients with HIV to be included on the transplant list 28, 30 .
Conclusion
All HIV-infected persons should be screened at regular intervals for a history of metabolic disease, dyslipidaemia, diabetes, hypertension, and alteration of body composition; cardiovascular risk and renal function should also be assessed. . Through the use of ultrasound-guided renal biopsy and automatic biopsy devices, percutaneous renal biopsy has become safe. Transjugular renal biopsy may represent a relatively safe and reliable alternative to conventional percutaneous biopsy in patients with risk factors for bleeding such as thrombopaenia 4, 5, 12 . Periodic monitoring of albuminuria, tubular parameters, and eGFR may be useful in the early diagnosis of patients at risk for acute or chronic kidney disease 24 . Estimates of kidney function have not been thoroughly validated in HIV-infected individuals and may be insensitive to early decrements in kidney function. The gold standards for determination of renal function are expensive and inconvenient. Although the current IDSA guidelines recommend using the Modification of Diet in Renal Disease (MDRD) equation to estimate kidney function in HIV-infected individuals, CKD Epidemiology Collaboration (CKD-EPI) is considered the most precise 25 . The new Japanese coefficient for eGFR based on insulin clearance data has been shown to be more accurate for the Japanese population than the previously reported equations 4, 25, 26, 29 . Serum cystatin C has been evaluated as an alternative or additional renal biomarker for estimating kidney function. However, the serum cystatin C level can be influenced by age, sex, race, and other non-renal factors 27, 29 . Periodic monitoring of urinary low molecular weight proteins, such as N-acetyl-β-d-glucosaminidase, β 2 microglobulin, α 1 microglobulin, etc., might be useful in early identification of tubular damage, especially in patients receiving HAART 12, 18 . In the pre-HAART era, dialysis was not offered to patients with HIV infection because of poor survival and with high infection rates. Currently, both peritoneal dialysis and haemodialysis are effective modes of renal replacement therapy in these patients 4, 11, 12 . Prior to the introduc- 
Results
We analysed 945 studies, out of which 578 were excluded for wrong population or intervention and 197 deemed unfit. After quality appraisal, 170 met the inclusion criteria for the review. The studies included in the review were grouped into two areas: nephropathy HIV associated and nephropathy HAART associated. Please refer Figure 1 .
Discussion
The incidence and spectrum of kidney disease in HIV-infected patients has changed considerably over the years. Identification of the cause of renal damage may be crucial in directing specific treatments. Renal biopsy should be considered in all HIVinfected patients with proteinuria, Figure 1 : Results of the research and/or treat metabolic diseases, impairment of the efficacy of HAART should be prevented by considering the possibility of pharmacokinetic interactions and compromised adherence. Treatment of HCV co-infection should be considered when patients have HCV-related nephropathy proved by renal biopsy. However, as yet, the safety and efficacy of interferon treatment for HCV infection in HIV-infected individuals has not been documented. Specialists in HIV and experts in metabolic diseases should consult each other.
